Opinion Review
Copyright ©The Author(s) 2021.
World J Gastroenterol. Jun 28, 2021; 27(24): 3429-3439
Published online Jun 28, 2021. doi: 10.3748/wjg.v27.i24.3429
Figure 1
Figure 1 Systemic therapy for advanced hepatocellular carcinoma. Note: First and second-line options may be presented as first-line options in parallel. Exclusion criteria in the REFLECT trial shown for lenvatinib[5]. AFP: Alpha-fetoprotein; BCLC: Barcelona Clinic Liver Cancer; ECOG: Eastern Cooperative Oncology Group; EH: Extrahepatic; HCV: Hepatitis C virus; HR: Hazard ratio; ORR: Overall response rate; PD-L1: Programmed death ligand 1; SOR: Sorafenib.